Abstract
Pulmonary Sarcomatoid Carcinoma (PSC) is a rare and highly malignant subtype of Non Small Cell Lung Cancer (NSCLC). In contrast to other types of lung cancers, recent retrospective studies demonstrated that PSC always shows frequent genetic mutations, high TMB and high PD L1 expression which indicates these patients might derive survival benefits from immune checkpoint inhibitors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have